Granix and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Granix (tbo-filgrastim), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zofran, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Granix. It is created by eHealthMe based on reports of 897 people who have side effects when taking Granix from the FDA, and is updated regularly.

What is Granix?

Granix has active ingredients of tbo-filgrastim. eHealthMe is studying from 897 Granix users. Check the latest studies of Granix.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,327 drugs and 3,591 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

On Jul, 10, 2026

897 people reported to have side effects when taking Granix.
Among them, 46 people (5.13%) have Agranulocytosis.

Among these 46 people:

How long have people been on Granix when they have Agranulocytosis? *

What is the gender of people who have Agranulocytosis when taking Granix? *

female: 72.22 %
male: 27.78 %

What is the age of people who have Agranulocytosis when taking Granix? *

What are other drugs people take besides Granix? *

What are other side effects people have besides Agranulocytosis? *

Fatigue (feeling of tiredness): 22 people, 47.83%
Thrombocytopenia (decrease of platelets in blood): 19 people, 41.30%
Nausea (feeling of having an urge to vomit): 15 people, 32.61%
Anaemia (lack of blood): 13 people, 28.26%
Leukopenia (less number of white blood cells in blood): 12 people, 26.09%
Malaise (a feeling of general discomfort or uneasiness): 11 people, 23.91%
Headache (pain in head): 10 people, 21.74%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 10 people, 21.74%
White Blood Cell Count Decreased: 10 people, 21.74%
Weakness: 10 people, 21.74%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 11 people, 23.91%
Breast Cancer Female: 8 people, 17.39%
Metastases To Bone (cancer spreads to bone): 7 people, 15.22%
Nausea (feeling of having an urge to vomit): 6 people, 13.04%
White Blood Cell Count Decreased: 5 people, 10.87%
Diarrhea: 3 people, 6.52%
Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 3 people, 6.52%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 3 people, 6.52%
Anaemia (lack of blood): 3 people, 6.52%
Diabetes: 2 people, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Granix and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Granix:

Granix (897 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

Browse all side effects of Granix:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,327 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,591 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on tbo-filgrastim (the active ingredients of Granix) and Granix (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.